Your browser is no longer supported. Please, upgrade your browser.
ENTA Enanta Pharmaceuticals, Inc. daily Stock Chart
Enanta Pharmaceuticals, Inc.
Index- P/E45.74 EPS (ttm)1.12 Insider Own5.20% Shs Outstand19.92M Perf Week2.48%
Market Cap1.05B Forward P/E- EPS next Y-2.73 Insider Trans0.00% Shs Float17.66M Perf Month0.00%
Income23.70M PEG- EPS next Q-0.82 Inst Own91.30% Short Float9.51% Perf Quarter-3.51%
Sales175.90M P/S5.97 EPS this Y-39.70% Inst Trans-2.26% Short Ratio10.56 Perf Half Y-15.17%
Book/sh24.39 P/B2.10 EPS next Y-90.90% ROA4.80% Target Price72.50 Perf Year-41.04%
Cash/sh17.30 P/C2.96 EPS next 5Y- ROE5.00% 52W Range38.40 - 89.25 Perf YTD-17.16%
Dividend- P/FCF30.28 EPS past 5Y4.30% ROI8.10% 52W High-42.66% Beta0.53
Dividend %- Quick Ratio20.60 Sales past 5Y33.90% Gross Margin- 52W Low33.28% ATR1.97
Employees132 Current Ratio20.60 Sales Q/Q-30.30% Oper. Margin6.40% RSI (14)51.68 Volatility3.09% 4.09%
OptionableYes Debt/Eq0.00 EPS Q/Q-253.30% Profit Margin13.50% Rel Volume0.72 Prev Close51.10
ShortableYes LT Debt/Eq0.00 EarningsMay 06 AMC Payout0.00% Avg Volume159.01K Price51.18
Recom2.70 SMA202.10% SMA50-0.23% SMA200-8.28% Volume113,945 Change0.16%
Mar-17-20Upgrade Robert W. Baird Neutral → Outperform $60
Nov-22-19Downgrade JMP Securities Mkt Outperform → Mkt Perform
Sep-26-19Downgrade JP Morgan Neutral → Underweight $86 → $57
May-24-19Initiated Wolfe Research Outperform $117
Apr-23-19Upgrade Berenberg Hold → Buy $80 → $120
Dec-13-18Initiated Berenberg Hold $80
Jun-06-18Initiated ROTH Capital Buy $133
Feb-08-18Downgrade JP Morgan Overweight → Neutral
Jan-02-18Downgrade RBC Capital Mkts Outperform → Sector Perform
Nov-21-17Reiterated RBC Capital Mkts Outperform $54 → $58
Sep-15-17Initiated RBC Capital Mkts Outperform $54
Jul-11-17Upgrade JMP Securities Mkt Perform → Mkt Outperform
Apr-28-16Downgrade JMP Securities Mkt Outperform → Mkt Perform
Feb-09-16Reiterated Barclays Underweight $16 → $18
Oct-23-15Upgrade JMP Securities Mkt Perform → Mkt Outperform $32
Oct-23-15Downgrade Barclays Equal Weight → Underweight $45 → $16
Aug-07-15Reiterated Barclays Equal Weight $35 → $45
Apr-06-15Initiated Deutsche Bank Buy $42
Mar-04-15Initiated Barclays Equal Weight $35
Aug-15-14Initiated FBR Capital Outperform $52
Jul-09-20 07:01AM  
Jun-29-20 07:00AM  
Jun-23-20 12:23PM  
Jun-11-20 07:02AM  
Jun-04-20 10:20PM  
May-23-20 09:58AM  
May-14-20 08:53AM  
May-12-20 07:30AM  
May-09-20 09:43PM  
May-07-20 12:01AM  
May-06-20 06:45PM  
Apr-29-20 12:34PM  
Apr-28-20 04:05PM  
Apr-17-20 10:19AM  
Mar-26-20 04:05PM  
Mar-13-20 07:00AM  
Mar-06-20 07:05AM  
Mar-04-20 08:09AM  
Feb-12-20 12:18AM  
Feb-06-20 05:15PM  
Feb-05-20 04:11PM  
Feb-03-20 07:27AM  
Jan-30-20 12:31PM  
Jan-24-20 07:30AM  
Jan-14-20 05:30AM  
Jan-09-20 07:30AM  
Jan-04-20 08:44AM  
Dec-30-19 07:30AM  
Dec-11-19 11:25AM  
Dec-09-19 07:38AM  
Dec-07-19 11:24PM  
Nov-22-19 08:18AM  
Nov-21-19 05:15PM  
Nov-17-19 08:42AM  
Nov-14-19 10:30AM  
Nov-11-19 10:21AM  
Nov-05-19 04:00PM  
Oct-27-19 10:29PM  
Oct-21-19 04:00PM  
Oct-12-19 10:03AM  
Oct-03-19 07:30AM  
Sep-30-19 04:48PM  
Sep-26-19 04:16PM  
Sep-25-19 04:28PM  
Sep-12-19 09:48AM  
Sep-10-19 07:30AM  
Aug-21-19 07:30AM  
Aug-19-19 02:54PM  
Aug-13-19 01:24PM  
Aug-07-19 12:37PM  
Aug-06-19 05:55PM  
Aug-02-19 08:51AM  
Jul-30-19 10:38AM  
Jul-15-19 07:30AM  
Jul-11-19 09:00AM  
Jul-08-19 07:30AM  
Jun-14-19 02:06PM  
Jun-10-19 04:00PM  
May-30-19 08:00AM  
May-15-19 08:23PM  
May-14-19 04:01PM  
May-07-19 09:00PM  
May-02-19 02:22PM  
Apr-30-19 10:32AM  
Apr-22-19 04:30PM  
Apr-11-19 10:13AM  
Apr-05-19 03:32PM  
Apr-04-19 10:00AM  
Apr-01-19 09:25AM  
Mar-27-19 05:24AM  
Mar-18-19 07:30AM  
Mar-11-19 07:30AM  
Feb-15-19 07:35AM  
Feb-10-19 11:22PM  
Feb-06-19 08:43PM  
Enanta Pharmaceuticals, Inc., a biotechnology company, focuses on the research and development of small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and hepatitis B virus. Enanta Pharmaceuticals, Inc. has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. The company was founded in 1995 and is headquartered in Watertown, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MELLETT PAUL JTreasurer and CFOMay 05Option Exercise1.211,7402,10042,824May 07 05:35 PM
Gardiner Nathaniel S.Sr. VP & General CounselMar 12Option Exercise30.003,00090,00027,605Mar 16 06:27 PM
MELLETT PAUL JTreasurer and CFOJan 02Sale60.8810,000608,80040,054Jan 06 06:17 PM
Gardiner Nathaniel S.Sr. VP & General CounselNov 22Option Exercise31.421,59250,02119,739Nov 25 05:01 PM
Luly Jay R.President and CEOOct 08Option Exercise14.187,05299,997638,246Oct 09 05:17 PM
Gardiner Nathaniel S.Sr. VP & General CounselSep 27Option Exercise30.005,000150,00019,871Sep 30 04:45 PM